Surface polysaccharides of Gram-negative enteric pathogens, in the form of capsule or lipopolysaccharide, are both essential virulence factors and protective antigens. The immunogenicity of these polysaccharide was enhanced by binding to carrier proteins. Sequential clinical studies in adults and in children in Vietnam, an area with a high attack rate of typhoid, showed that the capsular polysaccharide (Vi)conjugates bound to the recombinant Pseudomonas aeruginosa exoprotein A (rEPA) elicited high responses against typhi. In a Phase III trial, About 12,000 2-5 years old children injected with the conjugate vaccine showed no significant side reaction. The efficacy of Vi-rEPA was 91% after 27 months active surveillance. Salmonella paratyphi A, the second most common cause of enteric fever in Southeast Asia, were found to be safe and immunogenic in adults, teenagers and then 2-4 year old children. Escherichia coli O157, an emerging pathogen, causes hemolytic uremic syndrome in young children. Phase 1 study of O157 O-specific polysaccharide-rEPA conjugate demonstrated safety and immunogenicity in adult volunteers. A phase 2 study in children 2-5 year olds is planned. Non-toxic shiga toxin I are purified from mutant E. coli O157 and to be conjugated with O-specific polysaccharide for a bivalent vaccine. The major reservoir of E.coli O157 is cattle. LPS and O-specific polysaccharide conjugate showed to be immunogenic in cattle and a challenge study is planned to demonstrate the clearance of the carriage state in cattle. Vibrio cholera O1 and O139 are the major sero types in cholera infections. Conjugates synthesized with capsular polysaccharide of O139 elicited vibriocidal antibodies in mice. Clinical trials of these conjugates are planned.

Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2000
Total Cost
Indirect Cost
Name
U.S. National Inst/Child Hlth/Human Dev
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Ftacek, Peter; Nelson, Victor; Szu, Shousun C (2013) Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length. Glycoconj J 30:871-80
Moore, Sophie E; Jalil, Fehmida; Szu, Shousun Chen et al. (2008) Revaccination does not improve an observed deficit in antibody responses in Pakistani adults born of a lower birth weight. Vaccine 26:158-65
Ahmed, Amina; Li, Jianpin; Shiloach, Yossi et al. (2006) Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 193:515-21
Canh, Do Gia; Lin, Feng-ying Kimi; Thiem, Vu Dinh et al. (2004) Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 72:6586-8
Mai, Ngoc Lanh; Phan, Van Bay; Vo, Anh Ho et al. (2003) Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 349:1390-1
Lin, F Y; Ho, V A; Khiem, H B et al. (2001) The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 344:1263-9
Kossaczka, Z; Shiloach, J; Johnson, V et al. (2000) Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect Immun 68:5037-43
Konadu, E Y; Lin, F Y; Ho, V A et al. (2000) Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 68:1529-34
Kossaczka, Z; Lin, F Y; Ho, V A et al. (1999) Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 67:5806-10
Konadu, E; Donohue-Rolfe, A; Calderwood, S B et al. (1999) Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect Immun 67:6191-3